<DOC>
	<DOC>NCT02579382</DOC>
	<brief_summary>The study will evaluate the safety, tolerability, and efficacy of vesatolimod (formerly GS-9620) in adults with chronic hepatitis B (CHB) infection who are currently not being treated.</brief_summary>
	<brief_title>A Study of the Safety, Tolerability, and Efficacy of Vesatolimod in Combination With Tenofovir Disoproxil Fumarate (TDF) in Adults With Chronic Hepatitis B (CHB) Infection Who Are Currently Not Being Treated</brief_title>
	<detailed_description />
	<mesh_term>Hepatitis</mesh_term>
	<mesh_term>Hepatitis A</mesh_term>
	<mesh_term>Hepatitis, Chronic</mesh_term>
	<mesh_term>Hepatitis B</mesh_term>
	<mesh_term>Hepatitis B, Chronic</mesh_term>
	<mesh_term>Tenofovir</mesh_term>
	<criteria>Key Adult males or females between the ages of 1865 Chronic HBV infection HBV DNA â‰¥ 2000 IU/mL at screening Key Extensive bridging fibrosis or cirrhosis Received oral antiviral treatment for HBV or prolonged therapy with immunemodulators or biologics within 3 months of screening Coinfection with hepatitis C virus (HCV), HIV or hepatitis D virus (HDV) Chronic liver disease other than HBV Lactating or pregnant females or those that wish to become pregnant during the course of the study Note: Other protocol defined Inclusion/Exclusion criteria may apply.</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>65 Years</maximum_age>
	<verification_date>January 2017</verification_date>
	<keyword>HBV</keyword>
	<keyword>Hepatitis</keyword>
	<keyword>Liver Disease</keyword>
</DOC>